Extend your brand profile by curating daily news.

Creative Diagnostics Expands Liver Metabolism Product Line to Enhance Drug Safety Testing

By Advos

TL;DR

Creative Diagnostics' expanded hepatic metabolism products give pharmaceutical researchers a competitive edge by enabling more precise drug testing across multiple species to reduce clinical failure risks.

Creative Diagnostics now offers liver-specific fractions including Cytosol, Microsomes, and S9 Fractions from various species to support systematic in vitro metabolism studies for drug development.

These liver metabolism products help researchers develop safer medications by better understanding drug toxicity, potentially reducing harmful side effects and improving patient outcomes worldwide.

The liver generates both therapeutic and toxic metabolites, like ifosfamide producing an antitumor compound alongside nephrotoxic chloroacetaldehyde, highlighting complex organ interactions in drug metabolism.

Found this article helpful?

Share it with your network and spread the knowledge!

Creative Diagnostics Expands Liver Metabolism Product Line to Enhance Drug Safety Testing

Creative Diagnostics, a reagent supplier focused on biologics quality control, has expanded its comprehensive range of Products for Hepatic Metabolism. This new line of liver-specific fractions, including Liver Cytosol, Liver Microsomes, and Liver S9 Fractions from various species, supports pharmaceutical researchers and toxicologists in conducting critical in vitro metabolism studies.

The liver plays a central role in human metabolism, processing both beneficial and harmful substances. Its primary metabolic functions include carbohydrate metabolism, lipid and fatty acid metabolism, protein and amino acid metabolism, and drug metabolism. Most liver diseases result in varying degrees of hepatocyte damage and functional impairment, profoundly affecting these metabolic processes.

As the primary organ for drug metabolism and the main site of drug-induced toxicity, the liver accounts for over 50% of acute liver failure cases, leading to the withdrawal or restricted use of approved medications. Beyond hepatotoxicity, metabolites generated in the liver circulate systemically to other tissues and organs, including the kidneys, heart, brain, intestines, lungs, and tumors.

Harnessing drug-metabolite interactions between the liver and other organs can achieve desired therapeutic effects, but such interactions may also lead to unintended toxic side effects. For example, the pre-chemotherapy drug ifosfamide produces both the intended antitumor metabolite 4-hydroxy-IFO and the nephrotoxic metabolite chloroacetaldehyde. Therefore, interactions between the liver and other organs must be carefully considered in drug metabolism and toxicity studies.

Creative Diagnostics now offers an extensive range of hepatic metabolism products that enable researchers to study hepatic metabolic processes with high precision and reproducibility. This new product line includes liver products from various species, including humans, non-human primates, dogs, rats, rabbits, and minipigs. Core products include Liver Cytosol, Liver Microsomes, and Liver S9 Fractions.

"Precise metabolomic analysis is the cornerstone of successful drug development," said the Creative Diagnostics project manager. "By offering a liver metabolism testing product line spanning multiple species, we help our clients in the pharmaceutical industry bridge the gap between in vitro testing and in vivo outcomes, ultimately reducing the risk of clinical failure."

Drug metabolism studies are essential during drug evaluation, and researchers can learn more about the full catalog of Products for Hepatic Metabolism by visiting the Creative Diagnostics website at https://qbd.creative-diagnostics.com/products-for-hepatic-metabolism.html.

Curated from 24-7 Press Release

blockchain registration record for this content
Advos

Advos

@advos